Exenatide may reduce heavy drinking days and total alcohol intake in patients with obesity,22 while a cohort study from Denmark, including patients treated with GLP‐1 RAs (not including semaglutide or tirzepatide), demonstrated a 55% reduced risk of alcohol‐related events over 3 months.23 This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.